{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:08:23Z","timestamp":1780582103929,"version":"3.54.1"},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Veterans Health Administration"},{"DOI":"10.13039\/100006379","name":"Office of Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006379","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Sciences Research and Development"}],"content-domain":{"domain":["jpsychores.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychosomatic Research"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.jpsychores.2014.07.020","type":"journal-article","created":{"date-parts":[[2014,8,7]],"date-time":"2014-08-07T16:17:49Z","timestamp":1407428269000},"page":"184-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C"],"prefix":"10.1016","volume":"78","author":[{"given":"Marilyn","family":"Huckans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bret","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viva","family":"Wheaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Jaehnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carilyn","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kolessar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne Renee","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Berggren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Olavarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna W.","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth D.","family":"Flora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Loftis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychores.2014.07.020_bb0005","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/0091270003258669","article-title":"Global burden of disease (GBD) for hepatitis C","volume":"44","author":"Global Burden Of Hepatitis CWG","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0010","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1089-3261(02)00078-8","article-title":"Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002","volume":"7","author":"Seeff","year":"2003","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0015","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/ajg.2012.48","article-title":"Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office","volume":"107","author":"Yee","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0020","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0033-3182(09)70843-6","article-title":"Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder","volume":"50","author":"Hauser","year":"2009","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0025","doi-asserted-by":"crossref","first-page":"114","DOI":"10.7326\/0003-4819-158-2-201301150-00576","article-title":"Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review","volume":"158","author":"Chou","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0030","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0035","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0040","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jad.2004.04.002","article-title":"The phenomenology and treatment of interferon-induced depression","volume":"82","author":"Loftis","year":"2004","journal-title":"J Affect Disord"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0045","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1017\/S1355617703960048","article-title":"Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C","volume":"9","author":"Hilsabeck","year":"2003","journal-title":"J Int Neuropsychol Soc"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0050","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jad.2004.09.004","article-title":"Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C","volume":"84","author":"Amodio","year":"2005","journal-title":"J Affect Disord"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0055","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1159\/000348587","article-title":"A biopsychosocial model of interferon-alpha-induced depression in patients with chronic hepatitis C infection","volume":"82","author":"Baranyi","year":"2013","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0060","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2011.09.015","article-title":"Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition","volume":"56","author":"Byrnes","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0065","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/ajg.2010.3","article-title":"Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C","volume":"105","author":"Fontana","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0070","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/hep.21633","article-title":"Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C","volume":"45","author":"Fontana","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0075","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1017\/S1355617705050022","article-title":"Effect of interferon-alpha on cognitive functioning in patients with chronic hepatitis C","volume":"11","author":"Hilsabeck","year":"2005","journal-title":"J Int Neuropsychol Soc"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0080","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s002130000549","article-title":"Prefrontal cortical hypometabolism during low-dose interferon alpha treatment","volume":"152","author":"Juengling","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0085","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.clpt.2004.09.007","article-title":"Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin","volume":"77","author":"Kraus","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0090","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.eurpsy.2004.09.030","article-title":"Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNalpha): results from a prospective study","volume":"21","author":"Lieb","year":"2006","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0095","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.bbi.2007.12.009","article-title":"IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C","volume":"22","author":"Majer","year":"2008","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0100","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1478-3231.2011.02549.x","article-title":"Influence of hepatitis C virus on neurocognitive function in patients free from other risk factors: validation from therapeutic outcomes","volume":"31","author":"Pattullo","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0105","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.genhosppsych.2008.03.001","article-title":"Pegylated interferon alpha and ribavirin therapy may induce working memory disturbances in chronic hepatitis C patients","volume":"30","author":"Pawelczyk","year":"2008","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0110","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.biopsych.2010.04.019","article-title":"Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol","volume":"68","author":"Raison","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0115","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1468-1293.2007.00505.x","article-title":"Improved cognitive function as a consequence of hepatitis C virus treatment","volume":"8","author":"Thein","year":"2007","journal-title":"HIV Med"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0120","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1080\/15622970701714362","article-title":"Cognition in hepatitis C patients treated with pegylated interferon","volume":"10","author":"Wobrock","year":"2009","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0125","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40271-013-0005-4","article-title":"Physical, social, and psychological consequences of treatment for hepatitis C: a community-based evaluation of patient-reported outcomes","volume":"6","author":"Manos","year":"2013","journal-title":"Patient"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0130","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.4088\/JCP.12r07694","article-title":"Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis","volume":"73","author":"Udina","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0135","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3109\/15622975.2010.504282","article-title":"Is the interferon-alpha-triggered depressive episode a self-limited kind of depression? Four cases of persistent affective symptoms after antiviral treatment in HCV-infected individuals","volume":"11","author":"Galvao-de Almeida","year":"2010","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0140","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0168-8278(05)80402-7","article-title":"Suicide associated with alfa-interferon therapy for chronic viral hepatitis","volume":"21","author":"Janssen","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0145","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.psym.2013.05.001","article-title":"Escitalopram ameliorates prolonged depression with psychotic features induced by interferon therapy for hepatitis C infection: report of 2 cases","volume":"54","author":"Kajitani","year":"2013","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0150","first-page":"353","article-title":"Suicidal impulses in patients with chronic viral hepatitis C during or after therapy with interferon alpha","volume":"22","author":"Rifflet","year":"1998","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0155","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jhep.2012.07.037","article-title":"Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement","volume":"57","author":"Schaefer","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0160","series-title":"Diagnostic and statistical manual for mental disorders","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0165","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0170","series-title":"Wechsler test of adult reading","author":"Psychological Corporation","year":"2001"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0175","series-title":"Neuropsychological assessment battery","author":"Stern","year":"2003"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0180","series-title":"Beck Depression Inventory","author":"Beck","year":"1996"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0185","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.genhosppsych.2011.04.005","article-title":"Screening for depression in patients with hepatitis C using the Beck Depression Inventory-II: do somatic symptoms compromise validity?","volume":"33","author":"Patterson","year":"2011","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0190","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/0269881107069944","article-title":"Development and validation of the Generalized Anxiety Disorder Inventory (GADI)","volume":"21","author":"Argyropoulos","year":"2007","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0195","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11136-010-9769-3","article-title":"Psychometric evaluation of the Fatigue Severity Scale in patients with major depression","volume":"20","author":"Ferentinos","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0200","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1023\/A:1008960710415","article-title":"Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C","volume":"9","author":"Kleinman","year":"2000","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0205","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","article-title":"The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus","volume":"46","author":"Krupp","year":"1989","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0210","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singap"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0215","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00002508-200409000-00005","article-title":"Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain","volume":"20","author":"Keller","year":"2004","journal-title":"Clin J Pain"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0220","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jpain.2003.12.005","article-title":"Validation of the Brief Pain Inventory for chronic nonmalignant pain","volume":"5","author":"Tan","year":"2004","journal-title":"J Pain"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0225","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jpsychores.2012.10.012","article-title":"Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: a 16-week prospective study","volume":"74","author":"Loftis","year":"2013","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0230","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/brb3.200","article-title":"Multi-analyte profile (MAP) analysis of plasma immune proteins: Altered expression of peripheral immune factors is associated with neuropsychiatric symptom severity in adults with and without chronic hepatitis C virus infection","volume":"4","author":"Huckans","year":"2014","journal-title":"Brain Behav"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0235","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.neubiorev.2011.12.005","article-title":"Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression","volume":"36","author":"Leonard","year":"2012","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0240","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.neulet.2007.11.001","article-title":"Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha","volume":"430","author":"Loftis","year":"2008","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0245","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/da.20564","article-title":"Broad spectrum of cytokine abnormalities in panic disorder and posttraumatic stress disorder","volume":"26","author":"Hoge","year":"2009","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0250","first-page":"6","article-title":"A neuroimmunological perspective on anxiety disorders","volume":"27","author":"Hou","year":"2012","journal-title":"Hum Physiol"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0255","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jad.2012.04.004","article-title":"Inflammatory fatigue and sickness behaviour \u2014 lessons for the diagnosis and management of chronic fatigue syndrome","volume":"141","author":"Arnett","year":"2012","journal-title":"J Affect Disord"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0260","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jpain.2011.10.003","article-title":"Changes in plasma cytokines and their soluble receptors in complex regional pain syndrome","volume":"13","author":"Alexander","year":"2012","journal-title":"J Pain"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0265","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0034-7094(11)70029-0","article-title":"Cytokines and pain","volume":"61","author":"de Oliveira","year":"2011","journal-title":"Rev Bras Anestesiol"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0270","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1016\/j.pain.2011.09.005","article-title":"Cytokine biomarkers and chronic pain: association of genes, transcription, and circulating proteins with temporomandibular disorders and widespread palpation tenderness","volume":"152","author":"Slade","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0275","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/1099800411425857","article-title":"Pain and inflammation in women with early-stage breast cancer prior to induction of chemotherapy","volume":"15","author":"Starkweather","year":"2013","journal-title":"Biol Res Nurs"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0280","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/jgh.12028","article-title":"Current prospects for interferon-free treatment of hepatitis C in 2012","volume":"28","author":"Stedman","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0285","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3851\/IMP2567","article-title":"Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results","volume":"18","author":"Zeuzem","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0290","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa1213557","article-title":"Faldaprevir and deleobuvir for HCV genotype 1 infection","volume":"369","author":"Zeuzem","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0295","first-page":"S30","article-title":"Managing hepatitis C","volume":"10","author":"Bacon","year":"2004","journal-title":"Am J Manage Care"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0300","first-page":"227","article-title":"Risk and protective factors in interferon-induced depression: treatment strategies and clinical outcomes","volume":"28","author":"Loftis","year":"2008","journal-title":"Dir Psychiatry"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0305","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2165\/00023210-200519080-00009","article-title":"Interferon-alpha treatment of patients with Hepatitis C: the role of a comprehensive risk-benefit assessment","volume":"19","author":"Rifai","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0310","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1093\/cid\/cit266","article-title":"Management of mental health problems prior to and during treatment of hepatitis C virus infection in patients with drug addiction","volume":"57","author":"Schaefer","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0315","article-title":"Specific serotonin reuptake inhibitors prevent interferon-alpha-induced depression in patients with hepatitis C: a meta-analysis","author":"Jiang","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0320","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0033-3182(10)70722-2","article-title":"Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial","volume":"51","author":"Morasco","year":"2010","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0325","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jad.2007.01.007","article-title":"A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C","volume":"103","author":"Morasco","year":"2007","journal-title":"J Affect Disord"},{"key":"10.1016\/j.jpsychores.2014.07.020_bb0330","doi-asserted-by":"crossref","first-page":"94","DOI":"10.7326\/0003-4819-157-2-201207170-00006","article-title":"Escitalopram for the prevention of peginterferon-alpha2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial","volume":"157","author":"Schaefer","year":"2012","journal-title":"Ann Intern Med"}],"container-title":["Journal of Psychosomatic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022399914002840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022399914002840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T03:25:13Z","timestamp":1538364313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022399914002840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0022399914002840"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychores.2014.07.020","relation":{},"ISSN":["0022-3999"],"issn-type":[{"value":"0022-3999","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychosomatic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychores.2014.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}